PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
19.40M
Worse than MCRB's estimated revenue of 125.00M.
-3.88M
Better than MCRB's estimated ebitda of -101.69M.
-0.87
Worse than MCRB's estimated eps of -0.28.
-26.16M
Better than MCRB's estimated net income of -36.48M.
-3.88M
Better than MCRB's estimated ebit of -104.52M.
718.99M
Worse than MCRB's estimated sg&a expense of 349.92M.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-21.77M
Better than MCRB's ebitda of -77.31M.
100.00%
Better than MCRB's ebitda margin of -232.76%.
-22.21M
Better than MCRB's ebit of -86.20M.
100.00%
Better than MCRB's ebit margin of -259.53%.
447.00K
Better than MCRB's depreciation of 8.89M.
63.56M
Worse than MCRB's total cash of 253.62M.
100.00%
Worse than MCRB's cash as percentage of revenue of 763.56%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than MCRB's receivables as percentage of revenue of 28.26%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than MCRB's inventories as percentage of revenue of 0.00%.
4.34M
Worse than MCRB's accounts payable of 4.02M.
100.00%
Worse than MCRB's payables as percentage of revenue of 12.10%.
-253.00K
Worse than MCRB's capital expenditure of -591.00K.
100.00%
Worse than MCRB's capex as percentage of revenue of -1.78%.
4.99%
Better than MCRB's weighted average cost of capital (wacc) of 8.68%.
5.02%
Better than MCRB's cost of equity of 13.94%.
4.08%
Better than MCRB's cost of debt of 6.16%.
-0.23
Better than MCRB's beta of 2.05.
30.07M
Better than MCRB's diluted shares outstanding of 128.00M.
1.57M
Better than MCRB's total debt of 213.94M.
49.31M
Worse than MCRB's total equity of 110.08M.
50.89M
Worse than MCRB's total capital of 324.02M.
3.09%
Better than MCRB's debt weighting of 66.03%.
96.91%
Better than MCRB's equity weighting of 33.97%.
-22.04M
Better than MCRB's ebiat of -83.62M.
-17.50M
Better than MCRB's unlevered free cash flow of -113.45M.
2.00%
Equal to MCRB's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than MCRB's net debt of 85.97M.
71.33M
Better than MCRB's equity value of -3.26B.
2.37
Better than MCRB's equity value per share of -25.44.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.